Company intelligence / Profile preview

Gilead Sciences

Foster City, California, United Statesgilead.com ↗
Ownership
Public · GILD
Employees
~17600
Development stage
Commercial
01

Overview

Gilead has a broad portfolio of commercialized products in virology—especially HIV/AIDS and viral hepatitis—and oncology. Its HIV regimens are global standards of care. Hepatitis C drugs like Sovaldi and Harvoni have achieved high cure rates. Remdesivir was the first antiviral approved for COVID‑19 treatment. In oncology/cell therapy through Kite Pharma’s Yescarta and Tecartus CAR-Ts for lymphomas/leukemias are FDA-approved.

Therapeutic areas
OncologyImmunologyInfectious Diseases
Modalities
Small moleculesmonoclonal antibodies (mAbs)cell therapies (CAR-T)antivirals
Industry
Pharma
02

Drug pipeline

255 assets

254 more assets in the full pipeline.

03

Partnerships

Multiple licensing agreements with generic manufacturers for global access to antivirals[7]Collaborations with Galapagos NV in inflammation/fibrosis research[3]Academic partnerships worldwide; see below.
04

Financials

Market cap
$207B
Total revenue
$29.4B
Enterprise value
$226.8B

Beyond the preview

Go deeper on Gilead Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gilead Sciences.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call